Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome.

ABSTRACT:

Background

Neuroblastoma is the most common pediatric solid tumor of the sympathetic nervous system. Development of improved predictive tools for patients stratification is a crucial requirement for neuroblastoma therapy. Several studies utilized gene expression-based signatures to stratify neuroblastoma patients and demonstrated a clear advantage of adding genomic analysis to risk assessment. There is little overlapping among signatures and merging their prognostic potential would be advantageous. Here, we describe a new strategy to merge published neuroblastoma related gene signatures into a single, highly accurate, Multi-Signature Ensemble (MuSE)-classifier of neuroblastoma (NB) patients outcome.

Methods

Gene expression profiles of 182 neuroblastoma tumors, subdivided int

SUBMITTER: Cornero A 

PROVIDER: S-EPMC3314564 | biostudies-literature | 2012 Mar

REPOSITORIES: biostudies-literature